Myelodysplastic syndromes
L Adès, R Itzykson, P Fenaux - The Lancet, 2014 - thelancet.com
Myelodysplastic syndromes are clonal marrow stem-cell disorders, characterised by
ineffective haemopoiesis leading to blood cytopenias, and by progression to acute myeloid …
ineffective haemopoiesis leading to blood cytopenias, and by progression to acute myeloid …
Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
P Fenaux, D Haase, GF Sanz, V Santini… - Annals of …, 2014 - annalsofoncology.org
Myelodysplastic syndromes (MDS) are clonal haematopoietic stem cell (HSC) disorders
predominating in the elderly, characterised by ineffective haematopoiesis leading to blood …
predominating in the elderly, characterised by ineffective haematopoiesis leading to blood …
How we treat higher-risk myelodysplastic syndromes
MA Sekeres, C Cutler - Blood, The Journal of the American …, 2014 - ashpublications.org
Higher-risk myelodysplastic syndromes (MDS) are defined by patients who fall into higher-
risk group categories in the original or revised International Prognostic Scoring System …
risk group categories in the original or revised International Prognostic Scoring System …
IDH mutations are closely associated with mutations of DNMT3A, ASXL1 and SRSF2 in patients with myelodysplastic syndromes and are stable during disease …
Current information about clinical significance of IDH mutations in myelodysplastic
syndromes (MDS), their association with other genetic alterations and the stability during …
syndromes (MDS), their association with other genetic alterations and the stability during …
Validation of the revised international prognostic scoring system (IPSS-R) in patients with myelodysplastic syndrome: a multicenter study
J Neukirchen, M Lauseker, S Blum, A Giagounidis… - Leukemia research, 2014 - Elsevier
Abstract The revised IPSS (IPSS-R) was developed aiming at a better prognostication,
taking into account patients treated with best supportive care. We herein validated this …
taking into account patients treated with best supportive care. We herein validated this …
Myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN, U): natural history and clinical outcome by treatment strategy
CD DiNardo, N Daver, N Jain, N Pemmaraju… - Leukemia, 2014 - nature.com
Created in 2001 and retained in 2008, the World Health Organization (WHO) now
recognizes a distinct category of myelodysplastic/myeloproliferative neoplasms (MDS/MPN) …
recognizes a distinct category of myelodysplastic/myeloproliferative neoplasms (MDS/MPN) …
[HTML][HTML] Influence of Prognostic Factors on OverallSurvival in Myelodysplastic Syndromes
T Sotirova, A Stojanovic, S Genadieva-Stavric… - Materia socio …, 2014 - ncbi.nlm.nih.gov
Background: Accurate prediction of a patient's prognosis is useful to define the risk posed by
the disease. Age, gender, peripheral blood cytopenia, proportion of bone marrow (BM) …
the disease. Age, gender, peripheral blood cytopenia, proportion of bone marrow (BM) …
[HTML][HTML] The evaluation of the outcome in myelodysplastic patients by using non-cytogenetic prognostic scores
O Căzăceanu, AM Vlădăreanu, H Bumbea… - Journal of medicine …, 2014 - ncbi.nlm.nih.gov
Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic stem
cell disorders; they are characterized by ineffective hematopoiesis and a predilection to the …
cell disorders; they are characterized by ineffective hematopoiesis and a predilection to the …
[PDF][PDF] derHeinrich-Heine-UniversitätDüsseldorf Direktor: Univ.-Prof. Dr. med. RainerHaas
OKI AusderKlinikfürHämatologie - docserv.uni-duesseldorf.de
AusderKlinikfürHämatologie,OnkologieundKlinischeImmunologie derHeinrich-Heine-UniversitätDüsseldorf
Direktor:Univ.-Prof.Dr.m Page 1 AusderKlinikfürHämatologie,OnkologieundKlinischeImmunologie …
Direktor:Univ.-Prof.Dr.m Page 1 AusderKlinikfürHämatologie,OnkologieundKlinischeImmunologie …
Overall survival in myelodysplastic syndromes: a cohort study
T Sotirova, O Karanfilski, SG Stavric… - Journal of Research …, 2014 - repository.ukim.mk
Factors like age, gender, FAB subtypes, cytopenias, proportion of bone marrow (BM) blasts,
comorbidities, transfusion dependence, albumins, lactate dehydrogenase (LDH), karyotype …
comorbidities, transfusion dependence, albumins, lactate dehydrogenase (LDH), karyotype …